Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy
Citations Over TimeTop 15% of 2014 papers
Abstract
The pre-clinical and clinical development of viral vehicles for gene transfer increased in recent years, and a recombinant adeno-associated virus (rAAV) drug took center stage upon approval in the European Union. However, lack of standardization, inefficient purification methods and complicated retargeting limit general usability. We address these obstacles by fusing rAAV-2 capsids with two modular targeting molecules (DARPin or Affibody) specific for a cancer cell-surface marker (EGFR) while simultaneously including an affinity tag (His-tag) in a surface-exposed loop. Equipping these particles with genes coding for prodrug converting enzymes (thymidine kinase or cytosine deaminase) we demonstrate tumor marker specific transduction and prodrug-dependent apoptosis of cancer cells. Coding terminal and loop modifications in one gene enabled specific and scalable purification. Our genetic parts for viral production adhere to a standardized cloning strategy facilitating rapid prototyping of virus directed enzyme prodrug therapy (VDEPT).
Related Papers
- → Recombinant Adeno-associated Virus Transduction and Integration(2008)207 cited
- → Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus(2002)59 cited
- → Image-Guided Enzyme/Prodrug Cancer Therapy(2008)41 cited
- → Comparison of Gene Therapy with the Herpes Simplex Virus Thymidine Kinase Gene and the Bacterial Cytosine Deaminase Gene for the Treatment of Hepatocellular Carcinoma(1999)34 cited
- → 6. Adeno-Associated Virus Capsid Motif That Influences Tissue Specific Vector Transduction In Vivo(2013)